ViiV Healthcare announces positive phase III results from the BRIGHTE study of fostemsavir in heavily treatment-experienced patients with HIV

Data for investigational attachment inhibitor presented at the 16th European AIDS Conference in Milan

London, UK 27 October 2017 – ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, today announced results from the phase III BRIGHTE study of fostemsavir in heavily treatment-experienced (HTE) patients with HIV-1 infection. Following one week of treatment, HTE patients receiving fostemsavir added to a failing regimen experienced a greater reduction in HIV-1 viral load compared to patients receiving placebo, demonstrating statistical superiority of fostemsavir over placebo (0.79 log10 c/mL vs 0.17 log10 c/mL; p<0.0001).

After one week of blinded, randomized treatment, all patients received fostemsavir and an optimised background regimen. 54% of patients in the randomized cohort achieved virologic suppression (<40 c/mL) at 24 weeks of treatment with fostemsavir plus optimised background therapy. Most patients who received fostemsavir experienced at least one adverse event by week 24; the most frequently reported Grade 2-4 adverse events related to fostemsavir treatment were transient headache (2%), diarrhoea (2%) and nausea (4%).

“The results of the BRIGHTE study are very promising. Patients who participated in this study were failing their current antiretroviral regimens and had very limited treatment options left upon entry into the study, and the addition of fostemsavir to their failing regimen resulted in meaningful reductions in viral load at one week,” said John C Pottage, Jr, MD, Chief Scientific and Medical Officer, ViiV Healthcare. “Fostemsavir is a first-in-class attachment inhibitor, specifically developed for heavily treatment-experienced patients and is representative of ViiV Healthcare’s commitment to developing innovative medicines for all people living with HIV.”

Following ViiV Healthcare’s acquisition of fostemsavir, manufacturing is being transitioned to GSK sites, and plans for regulatory submissions will be dependent on collection of data required to support this change. Regulatory submissions are currently anticipated to take place in the 2019/2020 timeframe.

The adverse events and serious adverse events reported in the BRIGHTE study were generally reflective of the study population’s advanced disease state (severely immune-compromised with median BL CD4= 80 cells/µ). Seventeen deaths occurred by the week 24 database lock; most related to progression of AIDS.

BRIGHTE (NCT02362503) is a two-cohort (Randomized and Non-Randomized), phase 3 clinical trial evaluating the safety and efficacy of the HIV-1 attachment inhibitor fostemsavir in heavily treatment-experienced adults with HIV-1 infection. 371 enrolled patients had documented resistance, intolerability, and/or contraindication to all antiretroviral (ARV) agents in at least four of the six available ARV classes. Patients in the Randomized Cohort had to have one but no more than two fully active ARV classes remaining at baseline and were unable to form a viable antiretroviral regimen out of their remaining agents. These patients were randomized 3:1 to add blinded fostemsavir or blinded placebo (n=272) to their current failing regimen for eight days of functional monotherapy. Patients without any remaining fully active approved ARVs (n=99) were assigned to the Non-Randomized Cohort and received open-label fostemsavir plus optimized background therapy on Day 1. The primary endpoint of the study was mean change in log10 HIV-1 RNA between Day 1 and Day 8 for the Randomized Cohort. Beyond the eight-day blinded period, all patients in the Randomized Cohort received open-label fostemsavir plus optimised background therapy. Key secondary endpoints include durability of response at Weeks 24, 48 and 96, as well as safety and emergence of viral resistance.

– Ends –

Notes to editors

About fostemsavir
Fostemsavir (GSK 3684934, previously BMS-663068) is a first in class, HIV-1 attachment inhibitor that blocks viral attachment to CD4 by binding to gp120, acting at the first step of the viral life cycle.

About the patient population
Highly active antiretroviral medicines have significantly decreased mortality over the past 30 years, however, treatment failure and antiviral resistance remain a concern for HTE patients and their providers. Failure of HIV medicines to control the virus can result in selected mutation resistant to one or more antiretroviral medicines. Patient co-morbidities, tolerability, and safety issues may further decrease the number of anti-retroviral therapies available to design effective treatment regimens for these HTE patients. As a result, treatment options that address the complex needs of HTE people living with HIV remain a significant unmet need.

About ViiV Healthcare
ViiV Healthcare is a global specialist HIV company established in November 2009 by GlaxoSmithKline (LSE: GSK) and Pfizer (NYSE: PFE) dedicated to delivering advances in treatment and care for people living with HIV and for people who are at risk of becoming infected with HIV. Shionogi joined in October 2012. The company’s aim is to take a deeper and broader interest in HIV/AIDS than any company has done before and take a new approach to deliver effective and innovative medicines for HIV treatment and prevention, as well as support communities affected by HIV.

For more information on the company, its management, portfolio, pipeline, and commitment, please visit

About GSK
GSK – one of the world’s leading research-based pharmaceutical and healthcare companies – is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For further information, please visit

ViiV Healthcare Media enquiries:
Patricia O’Connor
+44 20 8047 5982

Marc Meachem
+1 919 483 8756

GSK Global Media enquiries:
Simon Steel
+44 (0) 20 8047 3763

David Daley
+44 (0) 20 8047 2615

Analyst/Investor enquiries:
Sarah Elton-Farr
+44 (0) 20 8047 5194

Tom Curry
+ 1 215 751 5419

Gary Davies
+44 (0) 20 8047 5503

James Dodwell
+44 (0) 20 8047 2406

Jeff McLaughlin
+1 215 751 7002

Cautionary statement regarding forward-looking statements
GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described under Item 3.D 'Principal risks and uncertainties' in the company's Annual Report on Form 20-F for 2016

Media Contacts

For US-specific media inquiries, email:

OR call +1 919 605 4521

For our corporate press office, email:

OR call +44 7557 290 420


Website images are not intended to imply that the models pictured have HIV.